<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of general medical care in nonpregnant adults with diabetes mellitus
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of general medical care in nonpregnant adults with diabetes mellitus
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of general medical care in nonpregnant adults with diabetes mellitus
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Deborah J Wexler, MD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Nathan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The estimated overall prevalence of diabetes mellitus among adults in the United States varies with race/ethnicity and ranges from 6.8 to 15.3 percent [
         <a href="#rid1">
          1
         </a>
         ]. The large majority of patients have type 2 diabetes. More health care resources are estimated to be spent on diabetes than on any other condition [
         <a href="#rid2">
          2
         </a>
         ]. Numerous factors, in addition to diabetes-associated complications, contribute to the impact of diabetes on quality of life and health care costs. Diabetes is associated with a high prevalence of depression [
         <a href="#rid3">
          3
         </a>
         ] and adversely impacts employment, absenteeism, and work productivity [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
         This review will provide an overview of general medical management for nonpregnant adult patients with diabetes, with a particular emphasis on nonglycemic management  (
         <a class="graphic graphic_table graphicRef63002" href="/z/d/graphic/63002.html" rel="external">
          table 1
         </a>
         ). The approach is consistent with guidelines from the American Diabetes Association (ADA) for health maintenance in patients with diabetes, which are updated yearly [
         <a href="#rid6">
          6-8
         </a>
         ]. Detailed discussions relating to screening, diagnosis, and initial evaluation of diabetes mellitus as well as management of hyperglycemia are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1761.html" rel="external">
          "Screening for type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1812.html" rel="external">
          "Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6790.html" rel="external">
          "Gestational diabetes mellitus: Glucose management and maternal prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4802.html" rel="external">
          "Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph utd-adt-cnt utd-adt-pathwys">
          ●
         </span>
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120430">
          (Related Pathway(s):
          <a class="utd-content-120430" href="/pathway/120430?topicRef=1750&amp;source=see_link">
           Diabetes: Initial therapy for non-pregnant adults with type 2 DM
          </a>
          .)
         </span>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20020082">
         <span class="h1">
          EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h2">
          Diabetes-related complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with diabetes require ongoing evaluation for diabetes-related complications.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We perform a history and physical examination two to four times yearly to obtain information on nutrition, physical activity, management of diabetes and cardiovascular risk factors, and diabetes-related complications  (
         <a class="graphic graphic_table graphicRef63002" data-inline-graphics="63002" href="/z/d/graphic/63002.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We check blood pressure and visually inspect the feet at every visit, and in addition, we perform a more thorough foot examination and refer patients for a dilated eye examination, usually annually. However, the frequency of eye examinations may vary based on the presence and severity of eye findings and other factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We measure glycated hemoglobin (A1C) every three months if A1C is not in the goal range and therapy requires adjustment. We measure A1C every six months in patients with stable glycemia who are meeting A1C goals. We measure fasting lipids, basic metabolic profile, and urine albumin-to-creatinine ratio annually.
        </p>
        <p>
        </p>
        <p>
         Morbidity from diabetes is a consequence of both macrovascular disease (atherosclerosis) and microvascular disease (retinopathy, nephropathy, and neuropathy). In type 2 diabetes, disease onset is often insidious, and diagnosis is therefore delayed. As a result, diabetes complications may be present at the time of diagnosis [
         <a href="#rid9">
          9
         </a>
         ], and their frequency increases over time  (
         <a class="graphic graphic_figure graphicRef58736" href="/z/d/graphic/58736.html" rel="external">
          figure 1
         </a>
         ). The development of complications can be delayed with management of hyperglycemia, hypertension, and dyslipidemia. Similarly, once present, the progression of these complications can be slowed with the same management strategies. In addition to management of hypertension, administration of an angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) and, if indicated, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, may specifically reduce progression of nephropathy. Laser therapy or intraocular injection of vascular endothelial growth factor (VEGF)-inhibiting agents can ameliorate advanced retinopathy and ameliorate vision loss. (See
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1773.html" rel="external">
          "Diabetic retinopathy: Prevention and treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3110.html" rel="external">
          "Moderately increased albuminuria (microalbuminuria) in type 1 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3089.html" rel="external">
          "Moderately increased albuminuria (microalbuminuria) in type 2 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3052.html" rel="external">
          "Treatment of diabetic kidney disease"
         </a>
         .)
        </p>
        <p>
         In the United States, the greatest absolute declines in people with diabetes have been reported for acute MI and stroke (between 1990 and 2010, 95.6 and 58.9 fewer cases per 10,000 persons per year for MI and stroke, respectively) [
         <a href="#rid10">
          10
         </a>
         ]. Other countries have similarly reported reductions in the rate of cardiovascular complications and lower-extremity amputation [
         <a href="#rid11">
          11-13
         </a>
         ]. (See
         <a class="local">
          'Reducing the risk of macrovascular disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h3">
          Routine eye examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with diabetes are at increased risk for vision loss, related both to refractive errors (correctable visual impairment), cataracts and glaucoma (which are more prevalent in persons with diabetes [
         <a href="#rid14">
          14,15
         </a>
         ]), and to retinopathy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Visual impairment
         </strong>
         – A study using data from the National Health and Nutrition Examination Survey (NHANES) in the United States found that 20 percent of Americans with diabetes aged 40 years and older without retinopathy (or with only mild and moderate nonproliferative diabetic retinopathy [NPDR]) had visual-related functional impairment [
         <a href="#rid16">
          16
         </a>
         ]. For those with severe NPDR or proliferative diabetic retinopathy, the prevalence was 48 percent. These data indicate the need for visual acuity assessment in addition to dilated eye examinations for retinopathy to identify individuals with reduced acuity, address treatable causes, and improve quality of life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diabetic retinopathy
         </strong>
         – Recommendations for the type and frequency of routine eye examinations vary based upon the type of diabetes mellitus, the presence of specific eye findings, and the level of risk factors, such as A1C levels  (
         <a class="graphic graphic_table graphicRef61833" data-inline-graphics="61833" href="/z/d/graphic/61833.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid7">
          7,17
         </a>
         ]. Serial examinations are indicated because of the increased incidence of retinopathy over time in patients with diabetes and the ability to intervene and reduce risk for vision loss with timely interventions  (
         <a class="graphic graphic_figure graphicRef70042" href="/z/d/graphic/70042.html" rel="external">
          figure 2
         </a>
         ). Screening for diabetic retinopathy is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1755.html" rel="external">
          "Diabetic retinopathy: Screening"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         General measures to reduce risk and progression of retinopathy include good glycemic and blood pressure control. Prevention and treatment of retinopathy is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1773.html" rel="external">
          "Diabetic retinopathy: Prevention and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Routine foot examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The feet should be visually inspected at each routine visit to identify problems with nail care, poorly fitting footwear resulting in barotrauma, fungal infections, and callus formation that may result in more severe foot problems. A comprehensive foot examination should be performed annually on patients with diabetes to identify risk factors predictive of ulcers and amputation [
         <a href="#rid7">
          7,18
         </a>
         ]. It can be accomplished in the primary care setting and should include inspection, assessment of pedal pulses, and testing for loss of protective sensation  (
         <a class="graphic graphic_table graphicRef59069" href="/z/d/graphic/59069.html" rel="external">
          table 3
         </a>
         ). Systematic screening examinations for neuropathic and vascular involvement of the lower extremities and careful inspection of feet may substantially reduce morbidity from foot problems. (See
         <a class="medical medical_review" href="/z/d/html/1749.html" rel="external">
          "Evaluation of the diabetic foot"
         </a>
         .)
        </p>
        <p>
         Foot problems due to vascular and neurologic disease are a common and important source of morbidity. Patients who may have neuropathy (based on abnormal results from a microfilament or other test [eg, Ipswich touch test]) (see
         <a class="medical medical_review" href="/z/d/html/1749.html" rel="external">
          "Evaluation of the diabetic foot", section on 'Assessment for loss of protective sensation'
         </a>
         ) or who have calluses or other foot deformities should be referred to clinicians with expertise in diabetic foot care (podiatrist, nurse, diabetes foot clinic, or other, depending on available local resources).
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Monitoring for increased urinary albumin excretion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measurement of the urine albumin-to-creatinine ratio in an untimed urinary sample is the preferred screening strategy in all patients with diabetes to detect elevation. It should be repeated yearly. Increased urinary protein excretion is the earliest clinical finding of diabetic nephropathy.
        </p>
        <p>
         Measurement of urinary albumin excretion can be deferred for five years after the onset of disease in patients with type 1 diabetes because diabetic nephropathy is uncommon before this time. Monitoring should begin at diagnosis in patients with type 2 diabetes because many have had diabetes for several years before diagnosis [
         <a href="#rid8">
          8
         </a>
         ]. Abnormal results should be repeated at least two or three times for confirmation over a three- to six-month period because of the large number of false positives that can occur [
         <a href="#rid19">
          19
         </a>
         ]. Fever, exercise, heart failure, and acute poor glycemic control are among the factors that can cause transient elevation in urinary albumin-to-creatinine ratio [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         The urine albumin-to-creatinine ratio test (mg/g) gives a quantitative result that correlates with the 24-hour urine values (mg/day) over a wide range of protein excretion. The normal rate of albumin excretion is less than 30 mg/day (20 mcg/min) (
         <a class="calc calc_professional" href="/z/d/html/95017.html" rel="external">
          calculator 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent urine albumin-to-creatinine ratio values between 30 and 300 mg/gram creatinine suggest that albumin excretion is between 30 and 300 mg/day. This is now called moderately increased albuminuria (historically called microalbuminuria) and is usually indicative of diabetic nephropathy (unless there is some other coexistent renal disease).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent urine albumin-to-creatinine ratio values above 300 mg/gram creatinine (or 300 mg/day if a 24-hour urine is collected) are considered to represent severely increased albuminuria (the new terminology for what was formerly called macroalbuminuria) and is also called proteinuria, clinical renal disease, or dipstick-positive proteinuria.
        </p>
        <p>
        </p>
        <p>
         The availability of effective therapy to prevent progression of kidney disease with ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, and SGLT2 inhibitors is the rationale for yearly screening of all patients with either type 1 or type 2 diabetes for increased albumin excretion. We typically continue yearly monitoring to assess response to therapy and/or to detect kidney disease progression; patients with an eGFR &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         , progressive decline in eGFR, or increasing albuminuria should be referred to a nephrologist whenever possible [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The treatment of increased urinary albumin excretion and diabetic nephropathy is reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3089.html" rel="external">
          "Moderately increased albuminuria (microalbuminuria) in type 2 diabetes mellitus", section on 'Effect of interventions on albuminuria'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3110.html" rel="external">
          "Moderately increased albuminuria (microalbuminuria) in type 1 diabetes mellitus", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3052.html" rel="external">
          "Treatment of diabetic kidney disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Screening for coronary heart disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         At every visit, we measure blood pressure, inquire about cardiorespiratory symptoms, and address additional cardiovascular risk factors (eg, smoking history, weight management, diet, sedentary lifestyle). We measure a fasting lipid profile at the initial medical evaluation and as indicated thereafter. (See
         <a class="local">
          'Blood pressure control'
         </a>
         below and
         <a class="local">
          'Lipid management'
         </a>
         below.)
        </p>
        <p>
         We do not routinely perform exercise stress testing in asymptomatic patients with diabetes, including patients with type 2 diabetes who are at higher risk for atherosclerotic cardiovascular disease (ASCVD) than people without diabetes. Routine screening does not improve outcomes beyond medical management of cardiac risk factors [
         <a href="#rid20">
          20
         </a>
         ]. For sedentary adults (age &gt;50 years) with diabetes who are beginning an exercise program, counsel initiation of a gentle exercise program with gradual progression as tolerated. We evaluate if typical or atypical signs or symptoms of ASCVD develop with exercise or are evident on examination.
        </p>
        <p>
         The increased risk for asymptomatic coronary artery disease in those with diabetes and other risk factors suggests that the decision to perform cardiac evaluation should be individualized, with consideration given to those at very high risk, such as patients with diabetes who also have atypical cardiac symptoms (eg, unexplained dyspnea), peripheral or carotid artery disease, or electrocardiogram abnormalities (eg, Q waves) [
         <a href="#rid20">
          20
         </a>
         ]. Despite the relatively high frequency of silent ischemia in patients with diabetes, identifying asymptomatic disease or providing early intervention beyond guideline-recommended ASCVD risk factor management has not been shown to improve outcomes in this population [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1551.html" rel="external">
          "Screening for coronary heart disease in patients with diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         The evaluation and treatment of patients with diabetes and known ASCVD is reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/84.html" rel="external">
          "Acute myocardial infarction: Patients with diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1581.html" rel="external">
          "Coronary artery revascularization in stable patients with diabetes mellitus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15053957">
         <span class="h2">
          Comorbid conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the microvascular and neuropathic complications of diabetes and coincident hypertension, obesity, dyslipidemia, and ASCVD, adults with type 2 diabetes are at risk for other comorbidities. These disorders, which may be present at diagnosis or may develop over time, include the following [
         <a href="#rid6">
          6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hearing impairment. (See
         <a class="medical medical_review" href="/z/d/html/6844.html" rel="external">
          "Etiology of hearing loss in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6850.html" rel="external">
          "Evaluation of hearing loss in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep apnea. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fatty liver disease. (See
         <a class="medical medical_review" href="/z/d/html/3625.html" rel="external">
          "Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anemia. In individuals with diabetes, anemia occurs often but not exclusively in association with chronic kidney disease. In addition,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         can be associated with vitamin B12 deficiency and, rarely, with anemia [
         <a href="#rid21">
          21
         </a>
         ].
         <strong>
         </strong>
         A complete blood count should be obtained at initial evaluation and annually [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">
          "Anemia of chronic disease/anemia of inflammation", section on 'Underlying disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Periodontal disease – Annual examination by a dentist is recommended for all patients with diabetes, even those without teeth [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6858.html" rel="external">
          "Overview of gingivitis and periodontitis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cognitive impairment [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5079.html" rel="external">
          "Risk factors for cognitive decline and dementia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depression and anxiety – Concurrent depression is highly prevalent among adults with diabetes [
         <a href="#rid24">
          24
         </a>
         ], underscoring the importance of screening at the time of diagnosis and routinely thereafter. (See
         <a class="medical medical_review" href="/z/d/html/83887.html" rel="external">
          "Screening for depression in adults", section on 'Screening tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes distress – Diabetes distress refers to stress, frustration, and being overwhelmed by the self-care responsibilities required for glycemic management. Clinicians should consider screening individuals for diabetes distress with validated surveys such as the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fprofessional.diabetes.org%2Fsites%2Fdefault%2Ffiles%2Fmedia%2Fada_mental_health_toolkit_questionnaires.pdf&amp;token=vZOLy7g9bwzw5Igs%2FX0CWVYMtGFB86ww6bkF%2FN%2FX8%2FUm1wC8zdmjaBKkzCZFoKCIwsgdH0zQpGsTONLQ%2BYloZ5cOb8G7p3%2Fear4KbEXvp6R5%2BCurgMR6N5w0TGOfnvlj&amp;TOPIC_ID=1750" target="_blank">
          Problem Areas in Diabetes Scale
         </a>
         or the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fprofessional.diabetes.org%2Fsites%2Fdefault%2Ffiles%2Fmedia%2Fada_mental_health_toolkit_questionnaires.pdf&amp;token=vZOLy7g9bwzw5Igs%2FX0CWVYMtGFB86ww6bkF%2FN%2FX8%2FUm1wC8zdmjaBKkzCZFoKCIwsgdH0zQpGsTONLQ%2BYloZ5cOb8G7p3%2Fear4KbEXvp6R5%2BCurgMR6N5w0TGOfnvlj&amp;TOPIC_ID=1750" target="_blank">
          Diabetes Distress Scale
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eating disorders. (See
         <a class="medical medical_review" href="/z/d/html/2093.html" rel="external">
          "Eating disorders: Overview of epidemiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fractures. (See
         <a class="medical medical_review" href="/z/d/html/2051.html" rel="external">
          "Bone disease in diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral arterial disease. (See
         <a class="medical medical_review" href="/z/d/html/15238.html" rel="external">
          "Screening for lower extremity peripheral artery disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">
          "Clinical features and diagnosis of lower extremity peripheral artery disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cancer – Some studies suggest an increased risk of certain cancers (liver, pancreas, endometrium, colon/rectum, breast, bladder) in patients with type 2 diabetes, possibly related to the coincident obesity [
         <a href="#rid25">
          25-31
         </a>
         ]. Adults with type 2 diabetes also have an increased risk of cancer mortality. In a systematic review of individual patient data from 97 prospective studies (820,900 patients), adults with diabetes compared with those without had an increased risk of death from cancer (hazard ratio [HR] 1.25, 95% CI 1.19-1.31) [
         <a href="#rid32">
          32
         </a>
         ]. The increased risk of death was associated specifically with cancers of the liver, pancreas, ovary, colorectum, lung, bladder, and breast. In addition, the relative risk was substantially reduced when adjusting for A1C levels in multivariate analyses, consistent with a mediating effect of hyperglycemia on cancer risk. (See
         <a class="medical medical_review" href="/z/d/html/2606.html" rel="external">
          "Epidemiology and risk factors for colorectal cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3599.html" rel="external">
          "Epidemiology and risk factors for hepatocellular carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2957.html" rel="external">
          "Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2480.html" rel="external">
          "Epidemiology and nonfamilial risk factors for exocrine pancreatic cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Diabetes mellitus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         For patients with signs or symptoms of any of these conditions, additional assessment is warranted. Patients with diabetes should undergo recommended age- and sex-specific cancer screening [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97819.html" rel="external">
          "Overview of preventive care in adults", section on 'Cancer screening'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15054334">
         <span class="h1">
          GLYCEMIC MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H15054361">
         <span class="h2">
          Blood glucose monitoring and target A1C
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with diabetes mellitus who use insulin or other glucose-lowering medications that can cause hypoglycemia should (at least periodically) self-monitor their glucose concentrations to help maintain safe, target-driven glucose levels. Self-monitoring is generally unnecessary in patients who are treated with diet alone or who take oral or injectable agents that do not cause hypoglycemia. (See
         <a class="medical medical_review" href="/z/d/html/1781.html" rel="external">
          "Glucose monitoring in the ambulatory management of nonpregnant adults with diabetes mellitus", section on 'Who should self-monitor?'
         </a>
         .)
        </p>
        <p>
         A1C goals in patients with diabetes should be tailored to the individual, balancing the demonstrated benefits with regard to prevention and delay of microvascular complications (intensive glycemic management) with the risk of hypoglycemia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A reasonable goal of therapy is an A1C value of ≤7.0 percent (53 mmol/mol) (
         <a class="calc calc_professional" href="/z/d/html/15628.html" rel="external">
          calculator 2
         </a>
         ) for most patients (using a Diabetes Control and Complications Trial [DCCT]/United Kingdom Prospective Diabetes Study [UKPDS]-aligned assay in which the upper limit of normal is 6.0 percent) [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1760.html" rel="external">
          "Glycemic control and vascular complications in type 2 diabetes mellitus", section on 'Choosing a glycemic target'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1751.html" rel="external">
          "Glycemic control and vascular complications in type 1 diabetes mellitus", section on 'Glycated hemoglobin (A1C)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In order to achieve this A1C goal, a fasting glucose of 80 to 130 mg/dL (4.4 to 7.2 mmol/L) and a postprandial glucose (90 to 120 minutes after a meal) less than 180 mg/dL (10 mmol/L) are generally given as targets, but higher achieved levels may suffice  (
         <a class="graphic graphic_table graphicRef121967" href="/z/d/graphic/121967.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The A1C goal should be set somewhat higher (eg, &lt;8 percent [&lt;64 mmol/mol]) for older patients and those with comorbidities, a history of severe hypoglycemia or other significant adverse medication effects or polypharmacy, or a limited life expectancy and little likelihood of benefit from intensive therapy. (See
         <a class="medical medical_review" href="/z/d/html/1776.html" rel="external">
          "Treatment of type 2 diabetes mellitus in the older patient", section on 'Controlling hyperglycemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A more stringent goal (A1C &lt;6 percent [&lt;42 mmol/mol]) is indicated during pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/4802.html" rel="external">
          "Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control", section on 'Target A1C level'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obtain an A1C at least twice yearly in patients who are meeting treatment goals and who have stable glycemic management and quarterly in patients whose therapy has changed or requires adjustment, or who are not meeting glycemic goals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If interpretation of the A1C result is problematic (ie, owing to hemoglobinopathies or in the setting of altered red cell turnover [eg, hemolytic anemia], resulting in discrepancies between A1C and true mean glycemia [detected by more intensive or targeted blood glucose monitoring or use of continuous glucose monitoring (CGM)]), other glycemic measurements (eg, time in range) should be used to assess degree of glycemic control. (See
         <a class="medical medical_review" href="/z/d/html/1807.html" rel="external">
          "Measurements of chronic glycemia in diabetes mellitus", section on 'Unexpected or discordant values'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         For individuals using CGM, a reasonable goal of therapy for most patients is a time spent in target glucose range (blood glucose between 70 to 180 mg/dL [3.9 mmol/L to 10 mmol/L]) &gt;70 percent, with time spent below range (blood glucose below 70 mg/dL [3.9 mmol/L]) &lt;4 percent [
         <a href="#rid33">
          33
         </a>
         ]. These targets generally apply to individuals with type 2 diabetes and those with type 1 diabetes who use an automated insulin delivery (AID) system but may be difficult to achieve for individuals with type 1 diabetes in the absence of AID use. For individuals with frailty or elevated risk of hypoglycemia, these goals should be adjusted to a time in range &gt;50 percent and time below range &lt;1 percent.
        </p>
        <p class="headingAnchor" id="H15054419">
         <span class="h2">
          Lifestyle intervention
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are three major components to nonpharmacologic therapy of blood glucose and overall health in type 2 diabetes (see
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Intensive lifestyle modification'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dietary modification
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exercise
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight reduction
        </p>
        <p>
        </p>
        <p>
         In addition to improving glycemia, lifestyle change and modest weight loss also reduce the development of obstructive sleep apnea, improve mobility and quality of life, and reduce the need for glucose-lowering and blood pressure medications [
         <a href="#rid35">
          35-38
         </a>
         ]. Diet and exercise are important components of therapy in patients with type 1 diabetes. (See
         <a class="medical medical_review" href="/z/d/html/1765.html" rel="external">
          "Nutritional considerations in type 1 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1766.html" rel="external">
          "Nutritional considerations in type 2 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1777.html" rel="external">
          "Exercise guidance in adults with diabetes mellitus", section on 'Exercise guidance'
         </a>
         .)
        </p>
        <p>
         Bariatric surgical treatment of patients with diabetes and obesity results in a large degree of sustained weight loss and, in parallel, large improvements in blood glucose management, including remissions of type 2 diabetes (see
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Bariatric (metabolic) surgery'
         </a>
         ). Pharmacotherapy for weight loss may also be used for patients with type 2 diabetes. (See
         <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">
          "Obesity in adults: Drug therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15054425">
         <span class="h2">
          Pharmacologic therapy for hyperglycemia
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph utd-adt-cnt utd-adt-pathwys">
          ●
         </span>
         <strong>
          Type 2 diabetes
         </strong>
         – Initiating
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         early in the course of type 2 diabetes, assuming that no contraindications are present, remains the consensus recommendation. (See
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus"
         </a>
         .)
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120430">
          (Related Pathway(s):
          <a class="utd-content-120430" href="/pathway/120430?topicRef=1750&amp;source=see_link">
           Diabetes: Initial therapy for non-pregnant adults with type 2 DM
          </a>
          .)
         </span>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The therapeutic options for patients who fail initial therapy with lifestyle intervention and
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         are to add a second oral or injectable agent, including insulin  (
         <a class="graphic graphic_figure graphicRef111617" href="/z/d/graphic/111617.html" rel="external">
          figure 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1801.html" rel="external">
          "Insulin therapy in type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Regardless of the initial response to therapy, the natural history of most patients with type 2 diabetes is for blood glucose concentrations and A1C to rise over time  (
         <a class="graphic graphic_figure graphicRef81706" href="/z/d/graphic/81706.html" rel="external">
          figure 4
         </a>
         ) [
         <a href="#rid39">
          39,40
         </a>
         ]. The UKPDS suggested that worsening beta cell dysfunction with decreased insulin release was primarily responsible for disease progression [
         <a href="#rid40">
          40
         </a>
         ]. More severe insulin resistance or decreased compliance with the dietary regimen also may contribute to progression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type 1 diabetes
         </strong>
         – Treatment of type 1 diabetes includes the coordination of meals/diet and activity with physiologic insulin replacement, which involves the frequent monitoring of blood glucose levels. (See
         <a class="medical medical_review" href="/z/d/html/1796.html" rel="external">
          "Management of blood glucose in adults with type 1 diabetes mellitus", section on 'Insulin regimens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          REDUCING THE RISK OF MACROVASCULAR DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prevention of cardiovascular morbidity is a major priority for patients with diabetes, especially type 2. Individuals with diabetes are at increased risk for developing and dying from atherosclerotic cardiovascular disease (ASCVD); compared with those without diabetes, people with diabetes have decreased life expectancy (six to eight years less) [
         <a href="#rid32">
          32,41-43
         </a>
         ]. At the time of diagnosis of type 2 diabetes, many patients already have one or more risk factors for macrovascular disease (obesity, hypertension, dyslipidemia, smoking) and many have evidence of overt atherosclerosis (past myocardial infarction [MI], ischemic changes on electrocardiogram [ECG], or peripheral vascular disease).
        </p>
        <p class="headingAnchor" id="H1486667581">
         <span class="h2">
          Multifactorial risk factor reduction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of ASCVD risk factors, including hypertension, hypercholesterolemia, and smoking, has been shown to reduce cardiovascular mortality. Smoking cessation is essential for patients who smoke. In addition, use of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (75 to 162 mg/day), and use of certain glucose-lowering medications in patients with or at high risk for ASCVD can reduce recurrent ASCVD events and mortality. (See
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Established cardiovascular or kidney disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Monotherapy failure'
         </a>
         .)
        </p>
        <p>
         The benefits of multifactorial risk factor reduction are illustrated by the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a Swedish cohort study (median follow-up 5.7 years), among nonsmoking patients with type 2 diabetes who had A1C, low-density lipoprotein (LDL) cholesterol, urinary albumin, and blood pressure within target ranges, there was little or no excess risk of death, MI, or stroke compared with the general population [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Steno-2 trial, 160 patients with type 2 diabetes and modestly elevated albuminuria were randomly assigned to either conventional therapy or an intensive therapy regimen, which included lifestyle modification, glycemic control (target A1C &lt;6.5 percent), blood pressure control (target &lt;140/85 mmHg for most of the study and &lt;130/80 mmHg for the last two years), and lipid-lowering therapy, angiotensin-converting enzyme (ACE) inhibitor regardless of blood pressure, and
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ]. After a mean of 7.8 years, patients on intensive therapy had a significant reduction in the primary aggregate endpoint of cardiovascular death, nonfatal MI, coronary artery bypass grafting, percutaneous coronary intervention, stroke, amputation, or peripheral vascular surgery (18 versus 38 percent, hazard ratio [HR] 0.47, 95% CI 0.22-0.74). Significant reductions were also seen in progression of nephropathy, retinopathy, and autonomic neuropathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After the intervention study ended, 130 remaining patients participated in an observational follow-up study (5.5 years), during which time all participants were encouraged to follow intensive multifactorial treatment regimens, and A1C values, blood pressure, body mass index (BMI), and cholesterol levels in the two groups became similar [
         <a href="#rid46">
          46
         </a>
         ]. During the entire follow-up period (13.3 years), there were fewer deaths (30 versus 50 percent) in the intensive therapy group (HR for death 0.54, 95% CI 0.32-0.89). Intensive therapy was also associated with a lower risk of cardiovascular deaths (HR 0.43, 95% CI 0.19-0.94), which was a predefined secondary endpoint. Progression of diabetic retinopathy, nephropathy, and autonomic neuropathy occurred less frequently in the intensive group. These results suggest a sustained benefit of multifactorial risk reduction.
        </p>
        <p>
        </p>
        <p>
         In spite of evidence that aggressive risk factor reduction lowers the risk of both micro- and macrovascular complications in patients with diabetes, a minority of adults with diabetes achieve all of the recommended goals for A1C, blood pressure control, and management of dyslipidemia [
         <a href="#rid45">
          45,47,48
         </a>
         ]. It is notable that only one patient in the observational Steno study described above reached all five treatment goals at the end of follow-up. Thus, renewed efforts to implement multifactorial risk factor reduction strategies early in the course of type 2 diabetes are necessary. (See
         <a class="local">
          'Adequacy of care'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Smoking cessation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A survey in the United States (2001 to 2010) found that the adjusted prevalence of cigarette smoking was lower and quit attempts higher among adults with versus without diabetes [
         <a href="#rid49">
          49
         </a>
         ]. A meta-analysis of many of the cardiovascular risk reduction trials showed that cessation of smoking had a much greater benefit on survival than most other interventions [
         <a href="#rid50">
          50
         </a>
         ]. These findings suggest that discontinuation of smoking is one of the most important aspects of therapy in patients with diabetes who smoke. (See
         <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">
          "Overview of smoking cessation management in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Aspirin
         </span>
        </p>
        <p class="headingAnchor" id="H1879585395">
         <span class="h3">
          Candidates
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the secondary prevention of ASCVD in patients with diabetes, we recommend
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (75 to 162 mg daily). For the primary prevention of ASCVD in patients with diabetes at increased cardiovascular risk (10-year risk &gt;10 percent), we suggest aspirin (75 to 162 mg daily), although the evidence supporting this approach is weak and needs to be balanced with the increased risk of gastrointestinal bleeding. We do not routinely use aspirin for the prevention of ASCVD in adults with diabetes at low risk (10-year ASCVD risk &lt;10 percent). (See
         <a class="local">
          'Guidelines'
         </a>
         below.)
        </p>
        <p>
         The decision to use
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for the prevention of cardiovascular events in patients with diabetes should be made using shared decision-making on an individual basis, taking into account potential benefits and risks (see
         <a class="local">
          'Bleeding'
         </a>
         below). It is likely that there is some level of risk of ASCVD events that would result in a positive benefit-to-risk ratio. Large trials investigating the role of aspirin for the primary prevention of cardiovascular events in patients with diabetes have been completed or are underway [
         <a href="#rid51">
          51-54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4157778065">
         <span class="h3">
          Prevention of cardiovascular events
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary prevention
         </strong>
         – The merits of daily
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         therapy in patients with existing ASCVD are widely accepted. A meta-analysis from the Antithrombotic Trialists' Collaboration of randomized trials of antiplatelet therapy for the secondary prevention of ASCVD in high-risk patients showed that aspirin produced statistically significant and clinically important reductions in the risk of subsequent MI, stroke, and vascular death among a wide range of high-risk patients (acute MI or ischemic stroke, unstable angina, prior MI or stroke, peripheral artery disease, and other high-risk groups) [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">
          "Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the subset of patients with diabetes, there was a nonsignificant, 7 percent decrease in serious cardiovascular events [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of dual antiplatelet therapy and the use of combination therapy with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         plus anticoagulant therapy are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">
          "Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk", section on 'Adjunctive therapies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary prevention
         </strong>
         – The benefits of daily
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for the primary prevention of ASCVD in patients with diabetes and ASCVD risk factors (but without known ASCVD) is uncertain [
         <a href="#rid56">
          56
         </a>
         ]. In a meta-analysis of 10 trials evaluating aspirin for the primary prevention of ASCVD in patients with diabetes, aspirin modestly but significantly reduced the risk of major cardiovascular events compared with placebo or no treatment (relative risk [RR] 0.90, 95% CI 0.81-0.99) [
         <a href="#rid57">
          57
         </a>
         ]. Aspirin did not significantly reduce the risk of any of the individual endpoints (MI, coronary heart disease, stroke, ASCVD, or all-cause mortality). There were differences in effect according to underlying ASCVD risk, sex, and compliance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a subsequent trial, 15,480 patients with diabetes (94 percent with type 2 diabetes) but no evidence of ASCVD were randomly assigned to
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (100 mg daily) or placebo [
         <a href="#rid54">
          54
         </a>
         ]. (Participants were also randomly assigned to receive 1 gram n-3 fatty acid or placebo once daily.) The majority of patients were taking statins and antihypertensive medication. After a mean follow-up of 7.4 years, serious vascular events (a composite of MI, stroke [excluding intracranial hemorrhage], transient ischemic attack, or death from any vascular cause [except intracranial hemorrhage]) occurred in a smaller proportion of patients in the aspirin group (8.5 versus 9.6 percent, rate ratio 0.88, 95% CI 0.79-0.97). Aspirin did not significantly reduce the risk of any of the individual endpoints. The benefits of aspirin in reducing serious vascular events were offset by an approximate 1 percent absolute increased risk of bleeding, largely gastrointestinal and extracranial. (See
         <a class="local">
          'Bleeding'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In exploratory analyses, the effects of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         on serious vascular events and on safety events did not clearly vary according to baseline patient characteristics, including group assignment to n-3 fatty acids and baseline ASCVD risk.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main adverse effect of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         is bleeding. In the trial described above, major bleeding events (the first occurrence of a composite of intracranial hemorrhage, sight-threatening bleeding in the eye, gastrointestinal bleeding, or bleeding that resulted in hospitalization, transfusion, or fatality) occurred in a higher proportion of patients in the aspirin group (4.1 versus 3.2 percent, rate ratio 1.29, 95% CI 1.09-1.52) [
         <a href="#rid54">
          54
         </a>
         ]. Aspirin did not significantly increase the risk of any of the individual endpoints. In a Japanese trial, however, there was an increase in nonfatal intracranial hemorrhage (23 versus 10 events) and subarachnoid hemorrhage (8 versus 4 events) in patients taking aspirin [
         <a href="#rid58">
          58
         </a>
         ]. Extracranial hemorrhage requiring transfusion or hospitalization was also more common in the aspirin group (62 versus 34 events, HR 1.85, 95% CI 1.22-2.81).
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         does not appear to increase retinal hemorrhagic complications in patients with diabetic retinopathy, even if advanced. In the Early Treatment Diabetic Retinopathy Study, patients with mild to severe nonproliferative or early proliferative diabetic retinopathy had one eye treated with scatter retinal photocoagulation. The 3711 participants were also randomly assigned to receive either aspirin (650 mg/day) or placebo. During the study, periodic fundus photography of the eyes not receiving photocoagulation detected vitreous or pre-retinal hemorrhages in 32 versus 30 percent of patients treated with aspirin or placebo, respectively [
         <a href="#rid59">
          59
         </a>
         ]. Approximately 40 percent of these hemorrhages produced a loss of visual acuity to less than 20/40. However, the severity and rate of resolution of these hemorrhages were not different between the aspirin- and placebo-treated groups. Similarly, in the large trial described above (15,480 patients with diabetes), the risk of sight-threatening bleeding did not differ between the aspirin and placebo groups (0.7 and 0.8 percent, respectively, rate ratio 0.89, 95% CI 0.62-1.27) [
         <a href="#rid54">
          54
         </a>
         ]. These studies, as well as a meta-analysis of other randomized clinical trials, concluded that there were no ocular contraindications to the use of aspirin (650 mg/day) in persons with diabetes who require this medicine for treatment of ASCVD or for other medical indications [
         <a href="#rid59">
          59,60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Guidelines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon these data, the American Diabetes Association (ADA) recommends the following approach [
         <a href="#rid20">
          20
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         (75 to 162 mg/day) is recommended for secondary prevention in patients with diabetes and a history of MI, vascular bypass, stroke or transient ischemic attack, peripheral vascular disease, claudication, or angina.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dual antiplatelet therapy (low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         plus a P2Y12 inhibitor) is reasonable for a year after an acute coronary syndrome. Longer-term treatment should be considered for patients with prior coronary intervention, high ischemic risk, and low bleeding risk to prevent major adverse cardiovascular events.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Combination therapy with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         plus low-dose
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         should be considered for patients with stable coronary and/or peripheral artery disease and low bleeding risk to prevent major adverse limb and cardiovascular events.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         (75 to 162 mg/day) should be considered for primary prevention in any patient with diabetes at increased cardiovascular risk (10-year risk &gt;10 percent) after a discussion of the benefits (reduction in major adverse cardiovascular events) versus increased risk of bleeding (primarily gastrointestinal). Increased cardiovascular risk may include most individuals &gt;50 years who have at least one additional cardiovascular risk factor (eg, cigarette smoking, hypertension, obesity, albuminuria, dyslipidemia, or a family history of coronary heart disease). The ADA recognizes that the evidence to support this recommendation is weak.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         is not recommended for ASCVD prevention for adults with diabetes at low risk (10-year risk &lt;5 percent), such as those with diabetes aged &lt;50 years with no major additional risk factors. In this population, the potential adverse effects from bleeding likely offset the potential benefits.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For adults &gt;21 years and &lt;50 years with diabetes who have multiple other cardiovascular risk factors (10-year risk between 5 and 10 percent), clinical judgement and shared decision-making is required.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          Clopidogrel
         </a>
         (75 mg/day) is recommended for patients with ASCVD and documented
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         allergy. (See
         <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">
          "Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk", section on 'Antiplatelet therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dual antiplatelet therapy is reasonable for up to one year after an acute coronary syndrome.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Blood pressure control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypertension is a common problem in type 1 and especially in type 2 diabetes. Early and effective treatment of high blood pressure is important, both to prevent cardiovascular disease (CVD) and to minimize the rate of progression of diabetic nephropathy and retinopathy.
        </p>
        <p>
         The ADA recommends measuring blood pressure at every routine diabetes visit, with individualization of treatment goals. Hypertension is defined as a systolic blood pressure ≥130 mmHg or a diastolic blood pressure ≥80 mmHg using an average of at least two measurements obtained on separate occasions [
         <a href="#rid20">
          20
         </a>
         ]. For most patients with hypertension, the ADA recommends treating to systolic and diastolic blood pressures of &lt;130 and &lt;80 mmHg, respectively, if these goals can be achieved safely [
         <a href="#rid20">
          20
         </a>
         ]. These targets are in accord with the 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines [
         <a href="#rid61">
          61,62
         </a>
         ]. The data supporting these goals and the choice of antihypertensive drugs are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">
          "Goal blood pressure in adults with hypertension", section on 'Patients with diabetes mellitus'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">
          "Treatment of hypertension in patients with diabetes mellitus", section on 'Choice of antihypertensive drug therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3052.html" rel="external">
          "Treatment of diabetic kidney disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Lipid management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipid abnormalities are common in patients with diabetes mellitus and undoubtedly contribute to the increase in risk of ASCVD. The ADA recommends screening for lipid disorders at the time of diabetes diagnosis, at an initial medical evaluation, and every five years thereafter if under age 40 and more often if indicated, as is usually the case in patients age 40 and older [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         We and others recommend lifestyle intervention (diet, weight loss, increased physical activity) to improve the lipid profile in all patients with diabetes [
         <a href="#rid20">
          20,63
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary prevention
         </strong>
         – The ADA recommends the initiation of at least moderate-intensity statin treatment for all adults with diabetes between the ages of 40 and 75 years [
         <a href="#rid20">
          20
         </a>
         ]. For patients without additional ASCVD risk factors and a baseline LDL cholesterol close to target, we individualize the decision to initiate statin therapy. This decision can be informed by use of an ASCVD risk calculator. (See
         <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">
          "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach", section on 'Estimate ASCVD risk using a risk calculator'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For individuals aged 40 to 75 years with diabetes and at least one additional cardiovascular disease risk factor, the ADA recommends high-intensity statin therapy with treatment targets of an LDL cholesterol &lt;70 mg/dL (1.8 mmol/L) and a reduction from baseline LDL cholesterol level of at least 50 percent. For individuals with diabetes aged 20 to 39 years or &gt;75 years, the decision to initiate statin therapy should be individualized. For adults with diabetes aged &gt;75 years in whom statin therapy was initiated previously, treatment continuation is reasonable. Approaches to lipid-lowering therapy in individuals with diabetes may vary, and ADA recommendations differ from those of other society guidelines. (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease", section on 'Diabetes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary prevention
         </strong>
         – In patients
         <strong>
          with
         </strong>
         clinical ASCVD, high-intensity statin therapy should be added to lifestyle intervention regardless of baseline lipid levels. The ADA treatment targets include an LDL cholesterol &lt;55 mg/dL (1.4 mmol/L) and a reduction from baseline LDL cholesterol level of at least 50 percent [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Therapy of dyslipidemia is discussed in detail separately, including additional pharmacotherapy options for patients who do not achieve adequate LDL cholesterol lowering on statin therapy. (See
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">
          "Hypertriglyceridemia in adults: Management", section on 'Treatment goals'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Diabetes medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         does not have adverse cardiovascular effects, and it appears to decrease cardiovascular events in certain populations. In trials primarily focusing on secondary prevention of CVD in patients with type 2 diabetes, there was a reduction in CVD outcomes with many sodium-glucose co-transporter 2 (SGLT2) inhibitors and many glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovascular effects of the diabetes medications are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">
          "Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Cardiovascular effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/109245.html" rel="external">
          "Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Cardiovascular effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">
          "Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          OTHER ASPECTS OF HEALTH MAINTENANCE
         </span>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Routine health maintenance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The potential exists for the clinician to overlook health maintenance not specifically targeted at diabetes, given the intensity and complexity of care required for prevention and treatment of complications of diabetes itself [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97819.html" rel="external">
          "Overview of preventive care in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Vaccination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with diabetes mellitus should receive  (
         <a class="graphic graphic_table graphicRef63002" href="/z/d/graphic/63002.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Influenza vaccination yearly, with adults 65 years of age and older administered the high-dose vaccine. In observational studies, influenza vaccine has been shown to be similarly effective in adults &lt;65 years of age with diabetes as in older patients with or without diabetes [
         <a href="#rid65">
          65,66
         </a>
         ]. The ADA advises that individuals with diabetes
         <strong>
          not
         </strong>
         receive the live, attenuated influenza vaccine that is nasally administered [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pneumococcal vaccination. The approach to pneumococcal vaccination in adults with predisposing conditions is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">
          "Pneumococcal vaccination in adults", section on 'Approach to vaccination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatitis B vaccination for unvaccinated adults younger than 60 years of age without evidence of prior infection. For older adult patients with diabetes, vaccination can be administered at the discretion of the treating clinician based upon the risk of acquiring hepatitis B virus, including the need for blood glucose monitoring, and the likelihood of an adequate immune response to vaccination. The effectiveness of the hepatitis B vaccine decreases with age [
         <a href="#rid67">
          67
         </a>
         ]. This recommendation is based on outbreaks of hepatitis B in patients who were undergoing blood glucose monitoring in nursing homes or assisted-living facilities, a subsequent analysis of the risk of acquiring hepatitis B virus among all patients with diabetes in the United States, and a cost-effectiveness analysis [
         <a href="#rid68">
          68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">
          "Hepatitis B virus immunization in adults", section on 'Indications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tetanus and diphtheria vaccinations, updated as per CDC guidelines. (See
         <a class="medical medical_review" href="/z/d/html/3897.html" rel="external">
          "Tetanus-diphtheria toxoid vaccination in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Herpes zoster, recombinant vaccine, based on CDC guidelines. (See
         <a class="medical medical_review" href="/z/d/html/8343.html" rel="external">
          "Vaccination for the prevention of shingles (herpes zoster)", section on 'Approach to vaccination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SARS-CoV-2 vaccination, based on CDC guidelines. People with type 2 diabetes are at increased risk of complications and death from coronavirus 2019 (COVID-19), and vaccine hesitancy should be assessed and addressed through evidence-based approaches. (See
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines", section on 'Dose and interval (for immunocompetent individuals)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128127.html" rel="external">
          "COVID-19: Issues related to diabetes mellitus in adults", section on 'Risk of severe COVID-19'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Human papilloma virus (HPV), in individuals with diabetes ≤26 years of age [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Women of childbearing age
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women in the reproductive years should receive counseling at regular intervals regarding contraception and pregnancy planning, including the need for tight glycemic control prior to pregnancy and the risk of pregnancy to the woman and fetus.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For women with diabetes who are contemplating pregnancy, prepregnancy counseling is important. Healthy pregnancy requires virtually normal blood glucose levels. Prior to pregnancy, glycemic management should be optimized and both angiotensin-converting enzyme (ACE) inhibitor and statin medications should be discontinued. (See
         <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">
          "Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management", section on 'Glycemic control'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For women who do not wish to become pregnant, the most reliable method of contraception should be used, when not contraindicated by other health concerns, because of the risk of hyperglycemia to the developing fetus. American Diabetes Association (ADA) guidelines state that the selection of a contraceptive method for an individual patient should use the same guidelines that apply to women without diabetes [
         <a href="#rid69">
          69
         </a>
         ]. Types of hormonal and nonhormonal contraception and important factors in choosing a contraceptive method are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">
          "Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management", section on 'Contraception and timing of pregnancy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          ADEQUACY OF CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite extensive data suggesting large benefits with preventive and treatment strategies and despite increasing media attention, many patients with diabetes are not receiving recommended levels of health care, including older patients [
         <a href="#rid70">
          70-72
         </a>
         ]; patients with limited proficiency in English, financial hardships, or complex comorbidities; and those from countries with fewer resources to manage diabetes [
         <a href="#rid73">
          73-75
         </a>
         ]. Even when recommended clinical data are obtained, rates of medication adjustment to address abnormal results are low [
         <a href="#rid76">
          76-78
         </a>
         ].
        </p>
        <p>
         There are several reasons for the large discrepancy between what should be done and what is being done, including clinical inertia and lack of an organized system for care [
         <a href="#rid79">
          79-82
         </a>
         ]. Several approaches have been tried in order to improve the care of patients with diabetes. These include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Diabetes mini-clinics" [
         <a href="#rid83">
          83,84
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Better organization and delivery of patient education [
         <a href="#rid85">
          85,86
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Structured behavioral intervention [
         <a href="#rid87">
          87,88
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management by nurse specialists under the supervision of a diabetologist [
         <a href="#rid89">
          89-91
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multidisciplinary disease management programs [
         <a href="#rid92">
          92-95
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group medical visits [
         <a href="#rid96">
          96,97
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Telecare intervention via web-based systems or mobile devices [
         <a href="#rid98">
          98-100
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         The growing use of electronic health records with embedded guidelines and reminders at the point of care about appropriate interventions may make it easier to deliver more appropriate diabetes care in a number of settings. Processes of care (performance of retinal examination, foot examination, A1C measurements, lipid testing, nephropathy screening, flu vaccination,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         therapy) may be more readily improved by disease management interventions than intermediate outcomes (blood pressure control, lipid control, or A1C level) [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9819673">
         <span class="h1">
          INDICATIONS FOR REFERRAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intensive insulin therapy is recommended for the majority of patients with type 1 diabetes, and therefore, patients with type 1 diabetes should be referred to an endocrinologist for management of diabetes [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
         The majority of patients with type 2 diabetes (greater than 90 percent) receive their routine care from primary care providers. A major unresolved controversy is the place of the generalist and the specialist in the treatment of patients with type 2 diabetes. Studies comparing care by specialists and generalists have generated conflicting findings [
         <a href="#rid102">
          102-106
         </a>
         ]. For most patients with type 2 diabetes, care can be delivered by primary care providers and their health care teams in coordination with other specialists where appropriate. Patients in need of insulin therapy should be managed by or in consultation with an endocrinologist, if at all possible.
        </p>
        <p>
         The decision to refer to an endocrinologist with expertise in diabetes management usually hinges on the complexity of the patient, the ability of the primary care team to achieve established goals of care in an individual, the need to manage complications, and other factors such as the capacity of the primary care practitioner to teach self-management skills such as monitoring and insulin injections. The ideal balance between primary and subspecialty care for the ever-increasing population of patients with type 2 diabetes will vary based on the resources and expertise available in different communities.
        </p>
        <p class="headingAnchor" id="H2676065203">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/104442.html" rel="external">
          "Society guideline links: Diabetes mellitus in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/119659.html" rel="external">
          "Society guideline links: Assessment of cardiovascular risk"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/140971.html" rel="external">
          "Society guideline links: Diabetic kidney disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15751.html" rel="external">
          "Patient education: The ABCs of diabetes (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15401.html" rel="external">
          "Patient education: Type 1 diabetes (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15402.html" rel="external">
          "Patient education: Type 2 diabetes (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15595.html" rel="external">
          "Patient education: Treatment for type 2 diabetes (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15847.html" rel="external">
          "Patient education: Diabetic retinopathy (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">
          "Patient education: Coping with high drug prices (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1736.html" rel="external">
          "Patient education: Type 1 diabetes: Overview (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/1743.html" rel="external">
          "Patient education: Type 2 diabetes: Overview (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/1737.html" rel="external">
          "Patient education: Type 2 diabetes: Treatment (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">
          "Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial and ongoing evaluation
         </strong>
         – Morbidity from diabetes involves both macrovascular (atherosclerosis) and microvascular (retinopathy, nephropathy, and neuropathy) disease. Interventions can limit end-organ damage, and therefore, patients with diabetes require initial and ongoing evaluation for diabetes-related complications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We perform a history and physical examination two to four times yearly to address current glycemic management as well as management of nutrition, physical activity, cardiovascular risk factors, and diabetes-related complications and comorbidities  (
         <a class="graphic graphic_table graphicRef63002" href="/z/d/graphic/63002.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Diabetes-related complications'
         </a>
         above and
         <a class="local">
          'Comorbid conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glycemic management and prevention of micro- and macrovascular complications
         </strong>
         – Achieving glycemic goals can minimize risks for retinopathy, nephropathy, and neuropathy in both type 1 and type 2 diabetes and has been shown to decrease the risk for cardiovascular disease (CVD) for type 1 diabetes. (See
         <a class="local">
          'Glycemic management'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1760.html" rel="external">
          "Glycemic control and vascular complications in type 2 diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1751.html" rel="external">
          "Glycemic control and vascular complications in type 1 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          A1C goals
         </strong>
         – Glycated hemoglobin (A1C) goals in patients with diabetes should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia. A reasonable goal of therapy is an A1C value of ≤7.0 percent for most patients (using an assay in which the upper limit of normal is 6.0 percent). Glycemic targets are generally set somewhat higher (eg, &lt;8 percent) for older adult patients and those with comorbidities or a limited life expectancy and little likelihood of benefit from intensive therapy. More stringent management (A1C &lt;6 percent) may be indicated during pregnancy. (See
         <a class="local">
          'Blood glucose monitoring and target A1C'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1760.html" rel="external">
          "Glycemic control and vascular complications in type 2 diabetes mellitus", section on 'Choosing a glycemic target'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4802.html" rel="external">
          "Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control", section on 'Target blood glucose values'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1751.html" rel="external">
          "Glycemic control and vascular complications in type 1 diabetes mellitus", section on 'Glycemic targets'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of cardiovascular morbidity
         </strong>
         – Prevention of cardiovascular morbidity is a major priority for patients with diabetes, especially type 2. Smoking cessation is essential for patients who smoke. Cardiovascular morbidity can also be significantly reduced with aggressive management of hypertension, cholesterol, use of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (75 to 162 mg/day), and use of certain glucose-lowering medications in patients with or at high risk for cardiovascular disease (CVD). (See
         <a class="local">
          'Reducing the risk of macrovascular disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">
          "Treatment of hypertension in patients with diabetes mellitus", section on 'Approach to lowering blood pressure'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Monotherapy failure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Delivery of care
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Many patients with diabetes are not receiving recommended levels of health care, and development of systems of care involving disease management principles may be important in delivering improved care. (See
         <a class="local">
          'Adequacy of care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intensive insulin therapy targeting physiologic insulin replacement is recommended for the majority of patients with type 1 diabetes, and therefore, patients with type 1 diabetes should be referred to an endocrinologist for management of diabetes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For most patients with type 2 diabetes, care can be delivered by primary care providers and their health care teams in coordination with other specialists where appropriate. Patients in need of multiple daily injections of insulin therapy should be managed by or in consultation with an endocrinologist, if at all possible. The decision to refer to an endocrinologist with expertise in diabetes management usually hinges on the complexity of the patient, the ability of the primary care team to achieve established goals of care in an individual, the need to manage complications, and other factors such as the capacity of the primary care practitioner to teach self-management skills such as monitoring and insulin injections. (See
         <a class="local">
          'Indications for referral'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H542556701">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges David McCulloch, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          https://www.cdc.gov/diabetes/data/statistics-report/diagnosed.html (Accessed on May 17, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dieleman JL, Baral R, Birger M, et al. US Spending on Personal Health Care and Public Health, 1996-2013. JAMA 2016; 316:2627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kan C, Silva N, Golden SH, et al. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care 2013; 36:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care 2018; 41:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunceli K, Bradley CJ, Nerenz D, et al. The impact of diabetes on employment and work productivity. Diabetes Care 2005; 28:2662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ElSayed NA, Aleppo G, Aroda VR, et al. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ElSayed NA, Aleppo G, Aroda VR, et al. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ElSayed NA, Aleppo G, Aroda VR, et al. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014; 370:1514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennon B, Leese GP, Cochrane L, et al. Reduced incidence of lower-extremity amputations in people with diabetes in Scotland: a nationwide study. Diabetes Care 2012; 35:2588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Booth GL, Kapral MK, Fung K, Tu JV. Recent trends in cardiovascular complications among men and women with and without diabetes. Diabetes Care 2006; 29:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vamos EP, Bottle A, Edmonds ME, et al. Changes in the incidence of lower extremity amputations in individuals with and without diabetes in England between 2004 and 2008. Diabetes Care 2010; 33:2592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquale LR, Kang JH, Manson JE, et al. Prospective study of type 2 diabetes mellitus and risk of primary open-angle glaucoma in women. Ophthalmology 2006; 113:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obrosova IG, Chung SS, Kador PF. Diabetic cataracts: mechanisms and management. Diabetes Metab Res Rev 2010; 26:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willis JR, Doan QV, Gleeson M, et al. Vision-Related Functional Burden of Diabetic Retinopathy Across Severity Levels in the United States. JAMA Ophthalmol 2017; 135:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DCCT/EDIC Research Group, Nathan DM, Bebu I, et al. Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. N Engl J Med 2017; 376:1507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017; 40:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mogensen CE, Vestbo E, Poulsen PL, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ElSayed NA, Aleppo G, Aroda VR, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016; 101:1754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Dental visits among dentate adults with diabetes--United States, 1999 and 2004. MMWR Morb Mortal Wkly Rep 2005; 54:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu J, Fang M, Pike JR, et al. Prediabetes, intervening diabetes and subsequent risk of dementia: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 2023; 66:1442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dibato J, Montvida O, Ling J, et al. Temporal trends in the prevalence and incidence of depression and the interplay of comorbidities in patients with young- and usual-onset type 2 diabetes from the USA and the UK. Diabetologia 2022; 65:2066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166:1871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007; 30:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemminki K, Li X, Sundquist J, Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist 2010; 15:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33:1674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2015; 350:g7607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liao WC, Tu YK, Wu MS, et al. Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis. BMJ 2015; 349:g7371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ElSayed NA, Aleppo G, Aroda VR, et al. 6. Glycemic Targets: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei N, Zheng H, Nathan DM. Empirically establishing blood glucose targets to achieve HbA1c goals. Diabetes Care 2014; 37:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30:1374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuna ST, Reboussin DM, Borradaile KE, et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep 2013; 36:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabag A, Chang CR, Francois ME, et al. The Effect of Exercise on Quality of Life in Type 2 Diabetes: A Systematic Review and Meta-analysis. Med Sci Sports Exerc 2023; 55:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franco OH, Steyerberg EW, Hu FB, et al. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007; 167:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 2015; 313:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tancredi M, Rosengren A, Svensson AM, et al. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med 2015; 373:1720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rawshani A, Rawshani A, Franzén S, et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2018; 379:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ji L, Hu D, Pan C, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med 2013; 126:925.e11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013; 368:1613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan AZ, Rock V, Zhang X, et al. Trends in cigarette smoking rates and quit attempts among adults with and without diagnosed diabetes, United States, 2001-2010. Prev Chronic Dis 2013; 10:E160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ 1993; 306:1313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Berardis G, Sacco M, Evangelista V, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007; 8:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolucci A. Aspirin for primary prevention of cardiovascular events in diabetes: still an open question. JAMA 2008; 300:2180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaziano JM, Greenland P. When should aspirin be used for prevention of cardiovascular events? JAMA 2014; 312:2503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018; 379:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capodanno D, Angiolillo DJ. Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Circulation 2016; 134:1579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabet Med 2017; 34:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014; 312:2510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chew EY, Klein ML, Murphy RP, et al. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch Ophthalmol 1995; 113:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergerhoff K, Clar C, Richter B. Aspirin in diabetic retinopathy. A systematic review. Endocrinol Metab Clin North Am 2002; 31:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:e13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Boer IH, Bakris G, Cannon CP. Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA 2018; 319:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73:e285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fenton JJ, Von Korff M, Lin EH, et al. Quality of preventive care for diabetes: effects of visit frequency and competing demands. Ann Fam Med 2006; 4:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau D, Eurich DT, Majumdar SR, et al. Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study. Thorax 2013; 68:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Looijmans-Van den Akker I, Verheij TJ, Buskens E, et al. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care 2006; 29:1771.
          </a>
         </li>
         <li class="breakAll">
          https://www.cdc.gov/diabetes/pubs/pdf/hepb_vaccination.pdf (Accessed on June 20, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011; 60:1709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ElSayed NA, Aleppo G, Aroda VR, et al. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lutfiyya MN, McCullough JE, Mitchell L, et al. Adequacy of diabetes care for older U.S. rural adults: a cross-sectional population based study using 2009 BRFSS data. BMC Public Health 2011; 11:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McBean AM, Yu X. The underuse of screening services among elderly women with diabetes. Diabetes Care 2007; 30:1466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kazemian P, Shebl FM, McCann N, et al. Evaluation of the Cascade of Diabetes Care in the United States, 2005-2016. JAMA Intern Med 2019; 179:1376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez A, Schillinger D, Warton EM, et al. Language barriers, physician-patient language concordance, and glycemic control among insured Latinos with diabetes: the Diabetes Study of Northern California (DISTANCE). J Gen Intern Med 2011; 26:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerr EA, Heisler M, Krein SL, et al. Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients' treatment priorities and self-management? J Gen Intern Med 2007; 22:1635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alegre-Díaz J, Herrington W, López-Cervantes M, et al. Diabetes and Cause-Specific Mortality in Mexico City. N Engl J Med 2016; 375:1961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grant RW, Buse JB, Meigs JB, University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care 2005; 28:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013; 36:3411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang M, Wang D, Coresh J, Selvin E. Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018. N Engl J Med 2021; 384:2219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001; 135:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodondi N, Peng T, Karter AJ, et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med 2006; 144:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pimouguet C, Le Goff M, Thiébaut R, et al. Effectiveness of disease-management programs for improving diabetes care: a meta-analysis. CMAJ 2011; 183:E115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egginton JS, Ridgeway JL, Shah ND, et al. Care management for Type 2 diabetes in the United States: a systematic review and meta-analysis. BMC Health Serv Res 2012; 12:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurwitz B, Goodman C, Yudkin J. Prompting the clinical care of non-insulin dependent (type II) diabetic patients in an inner city area: one model of community care. BMJ 1993; 306:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacKinnon M. General practice diabetes care: the past, the present and the future. Diabet Med 1990; 7:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gruesser M, Bott U, Ellermann P, et al. Evaluation of a structured treatment and teaching program for non-insulin-treated type II diabetic outpatients in Germany after the nationwide introduction of reimbursement policy for physicians. Diabetes Care 1993; 16:1268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sperl-Hillen J, Beaton S, Fernandes O, et al. Comparative effectiveness of patient education methods for type 2 diabetes: a randomized controlled trial. Arch Intern Med 2011; 171:2001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillay J, Armstrong MJ, Butalia S, et al. Behavioral Programs for Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis. Ann Intern Med 2015; 163:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillay J, Armstrong MJ, Butalia S, et al. Behavioral Programs for Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson DM, Kozak SE, Sheps S. Insulin adjustment by a diabetes nurse educator improves glucose control in insulin-requiring diabetic patients: a randomized trial. CMAJ 1999; 161:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legorreta AP, Peters AL, Ossorio RC, et al. Effect of a comprehensive nurse-managed program: an HMO prospective study. Am J Manag Care 1996; 2:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang Y, Long Q, Jackson SL, et al. Nurse Practitioners, Physician Assistants, and Physicians Are Comparable in Managing the First Five Years of Diabetes. Am J Med 2018; 131:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinet LM, Osmick MJ, Ahmed T, Villagra VG. A cohort study of the impact of a national disease management program on HEDIS diabetes outcomes. Dis Manag 2005; 8:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothman RL, Malone R, Bryant B, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med 2005; 118:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mangione CM, Gerzoff RB, Williamson DF, et al. The association between quality of care and the intensity of diabetes disease management programs. Ann Intern Med 2006; 145:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagidipati NJ, Nelson AJ, Kaltenbach LA, et al. Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial. JAMA 2023; 329:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Housden L, Wong ST, Dawes M. Effectiveness of group medical visits for improving diabetes care: a systematic review and meta-analysis. CMAJ 2013; 185:E635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papadakis A, Pfoh ER, Hu B, et al. Shared Medical Appointments and Prediabetes: The Power of the Group. Ann Fam Med 2021; 19:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang Z, Tao H, Meng Q, Jing L. Management of endocrine disease. Effects of telecare intervention on glycemic control in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Eur J Endocrinol 2015; 172:R93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montori VM, Helgemoe PK, Guyatt GH, et al. Telecare for patients with type 1 diabetes and inadequate glycemic control: a randomized controlled trial and meta-analysis. Diabetes Care 2004; 27:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang X, Wang Q, Yang X, et al. Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis. Diabet Med 2011; 28:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holt RIG, DeVries JH, Hess-Fischl A, et al. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2021; 44:2589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verlato G, Muggeo M, Bonora E, et al. Attending the diabetes center is associated with increased 5-year survival probability of diabetic patients: the Verona Diabetes Study. Diabetes Care 1996; 19:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenfield S, Rogers W, Mangotich M, et al. Outcomes of patients with hypertension and non-insulin dependent diabetes mellitus treated by different systems and specialties. Results from the medical outcomes study. JAMA 1995; 274:1436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenfield S. Comparison by systems and specialties of medical outcomes in patients with hypertension and non-insulin dependent diabetes mellitus. Am J Manag Care 1996; 2:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho M, Marger M, Beart J, et al. Is the quality of diabetes care better in a diabetes clinic or in a general medicine clinic? Diabetes Care 1997; 20:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zgibor JC, Songer TJ, Kelsey SF, et al. Influence of health care providers on the development of diabetes complications: long-term follow-up from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2002; 25:1584.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1750 Version 102.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.cdc.gov/diabetes/data/statistics-report/diagnosed.html" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : https://www.cdc.gov/diabetes/data/statistics-report/diagnosed.html (Accessed on May 17, 2019).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28027366" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : US Spending on Personal Health Care and Public Health, 1996-2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23349152" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A systematic review and meta-analysis of the association between depression and insulin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29567642" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Economic Costs of Diabetes in the U.S. in 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16249536" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The impact of diabetes on employment and work productivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36507651" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36507636" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36507634" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1516497" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24738668" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Changes in diabetes-related complications in the United States, 1990-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23011727" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Reduced incidence of lower-extremity amputations in people with diabetes in Scotland: a nationwide study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16373892" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Recent trends in cardiovascular complications among men and women with and without diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20833865" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Changes in the incidence of lower extremity amputations in individuals with and without diabetes in England between 2004 and 2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16757028" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Prospective study of type 2 diabetes mellitus and risk of primary open-angle glaucoma in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20474067" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Diabetic cataracts: mechanisms and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28750122" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Vision-Related Functional Burden of Diabetic Retinopathy Across Severity Levels in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28423305" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27999003" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Diabetic Neuropathy: A Position Statement by the American Diabetes Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7497874" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36507632" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26900641" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16304554" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Dental visits among dentate adults with diabetes--United States, 1999 and 2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37221246" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Prediabetes, intervening diabetes and subsequent risk of dementia: the Atherosclerosis Risk in Communities (ARIC) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36059021" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Temporal trends in the prevalence and incidence of depression and the interplay of comorbidities in patients with young- and usual-onset type 2 diabetes from the USA and the UK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17000944" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17327321" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Prospective study of hyperglycemia and cancer risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20479278" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Risk of cancer following hospitalization for type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20587728" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Diabetes and cancer: a consensus report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17397032" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Diabetes mellitus and risk of breast cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25555821" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25556126" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21366474" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Diabetes mellitus, fasting glucose, and risk of cause-specific death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36507646" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : 6. Glycemic Targets: Standards of Care in Diabetes-2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24513588" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Empirically establishing blood glucose targets to achieve HbA1c goals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11832527" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17363746" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23633746" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36924331" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The Effect of Exercise on Quality of Life in Type 2 Diabetes: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9742976" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7589820" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17563022" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25562264" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26510021" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Excess Mortality among Persons with Type 2 Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30110583" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12556541" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18256393" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Effect of a multifactorial intervention on mortality in type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23810406" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23614587" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Achievement of goals in U.S. diabetes care, 1999-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24050530" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Trends in cigarette smoking rates and quit attempts among adults with and without diagnosed diabetes, United States, 2001-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8518573" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17725825" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18997199" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Aspirin for primary prevention of cardiovascular events in diabetes: still an open question.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25402671" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : When should aspirin be used for prevention of cardiovascular events?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30146931" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11786451" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27729421" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27086572" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25401325" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7826294" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12227131" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Aspirin in diabetic retinopathy. A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29133356" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29543954" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30423393" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16449394" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Quality of preventive care for diabetes: effects of visit frequency and competing demands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23535212" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16873778" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16873778" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22189894" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36507645" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22177279" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Adequacy of diabetes care for older U.S. rural adults: a cross-sectional population based study using 2009 BRFSS data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17351285" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The underuse of screening services among elderly women with diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31403657" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Evaluation of the Cascade of Diabetes Care in the United States, 2005-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20878497" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Language barriers, physician-patient language concordance, and glycemic control among insured Latinos with diabetes: the Diabetes Study of Northern California (DISTANCE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17647065" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients' treatment priorities and self-management?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27959614" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Diabetes and Cause-Specific Mortality in Mexico City.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15677789" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23877982" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34107181" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11694107" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Clinical inertia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16585661" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21149524" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Effectiveness of disease-management programs for improving diabetes care: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22439920" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Care management for Type 2 diabetes in the United States: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8461815" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Prompting the clinical care of non-insulin dependent (type II) diabetic patients in an inner city area: one model of community care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2137760" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : General practice diabetes care: the past, the present and the future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8404431" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Evaluation of a structured treatment and teaching program for non-insulin-treated type II diabetic outpatients in Germany after the nationwide introduction of reimbursement policy for physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21986350" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Comparative effectiveness of patient education methods for type 2 diabetes: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26414227" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Behavioral Programs for Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26414020" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Behavioral Programs for Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10551191" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Insulin adjustment by a diabetes nurse educator improves glucose control in insulin-requiring diabetic patients: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Effect of a comprehensive nurse-managed program: an HMO prospective study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28893514" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Nurse Practitioners, Physician Assistants, and Physicians Are Comparable in Managing the First Five Years of Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15815157" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : A cohort study of the impact of a national disease management program on HEDIS diabetes outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15745726" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16847293" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The association between quality of care and the intensity of diabetes disease management programs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36877177" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23939218" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Effectiveness of group medical visits for improving diabetes care: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34180846" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Shared Medical Appointments and Prediabetes: The Power of the Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25227131" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Management of endocrine disease. Effects of telecare intervention on glycemic control in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15111526" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Telecare for patients with type 1 diabetes and inadequate glycemic control: a randomized controlled trial and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21392066" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34593612" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8742563" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Attending the diabetes center is associated with increased 5-year survival probability of diabetic patients: the Verona Diabetes Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7474189" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Outcomes of patients with hypertension and non-insulin dependent diabetes mellitus treated by different systems and specialties. Results from the medical outcomes study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Comparison by systems and specialties of medical outcomes in patients with hypertension and non-insulin dependent diabetes mellitus
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9096962" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Is the quality of diabetes care better in a diabetes clinic or in a general medicine clinic?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12196431" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Influence of health care providers on the development of diabetes complications: long-term follow-up from the Pittsburgh Epidemiology of Diabetes Complications Study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
